Essential thrombocythemia (ET) is a rare chronic myeloproliferative neoplasm characterized by an abnormally high platelet count. According to Radiopaedia (2025), ET has an incidence of approximately 1.2–3.0 per 100,000 people, most commonly affecting individuals aged 55–65 years, with a higher prevalence in females. The growing focus on developing advanced therapeutics is driving pipeline expansion. According to the essential thrombocythemia (et) pipeline analysis by expert market research, the market is expected to witness steady growth in the coming years, supported by increasing R&D, evolving treatment guidelines, and the emergence of targeted therapies.
Major companies involved in the essential thrombocythemia (ET) pipeline analysis include Kartos Therapeutics, Inc., Imago BioSciences, Inc., and others.
Leading drugs currently in the pipeline include KRT-232, JNJ-88549968, AJ1-11095, and others.
The essential thrombocythemia (ET) drug pipeline is expected to grow due to increased R&D in JAK2 inhibitors, novel targeted therapies, and rising clinical trial activity for mutation-specific treatments.
The Essential Thrombocythemia (ET) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into essential thrombocythemia (ET) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for essential thrombocythemia (ET). The essential thrombocythemia (ET) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The essential thrombocythemia (ET) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with essential thrombocythemia (ET) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to essential thrombocythemia (ET).
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Essential thrombocythemia (ET) is a rare, chronic blood disorder characterized by the overproduction of platelets by abnormal stem cells in the bone marrow. This condition may lead to blood clots, bleeding, or, over time progression to myelofibrosis or acute leukemia.
Essential thrombocythemia is treated with medications like hydroxyurea or anagrelide to reduce platelet counts and prevent complications. Interferons may also be used for disease control. In June 2025, the phase 3 SURPASS-ET trial presented at the ASCO Annual Meeting showed that ropeginterferon alfa-2b outperformed anagrelide as a second-line therapy for essential thrombocythemia, demonstrating superior efficacy, lower adverse event rates, and significant molecular response.
According to Radiopaedia (2025), essential thrombocythemia has an incidence of approximately 1.2–3.0 cases per 100,000 individuals, with a higher prevalence observed in females aged 55–65 years. As per Ayalew Tefferi et al. (2025), in the United States, the annual incidence rate is 1.5 per 100,000 persons. These epidemiological insights are crucial for assessing the essential thrombocythemia drug development landscape, supporting targeted pipeline advancement and therapeutic planning across affected demographics.
This section of the report covers the analysis of essential thrombocythemia (ET) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The essential thrombocythemia (ET) pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total essential thrombocythemia (ET) clinical trials at 50%, showcasing strong momentum in mid-stage development. Phase I contributes nearly 31%, indicating a healthy influx of early innovation. Phase III holds 19%, reflecting promising advancements nearing approval. This balanced progression signals a vibrant pipeline poised to enhance therapeutic outcomes and market growth.
The drug molecule categories covered under the essential thrombocythemia (ET) pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The essential thrombocythemia (ET) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for essential thrombocythemia (ET). Lysine-specific demethylase 1 (LSD1) inhibitors are gaining attention in the essential thrombocythemia treatment pipeline. For instance, Bomedemstat, an oral LSD1 inhibitor developed by Merck, is currently being evaluated in Phase 3 clinical trials. It works by targeting abnormal hematopoietic stem cell proliferation, aiming to improve clinicohematologic response and symptom control in patients with essential thrombocythemia.
The EMR report for the essential thrombocythemia (ET) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed essential thrombocythemia (ET) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in essential thrombocythemia (ET) clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for essential thrombocythemia (ET). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of essential thrombocythemia (ET) drug candidates.
Navtemadlin (KRT-232), developed by Kartos Therapeutics, Inc., is currently being evaluated in the global Phase 2/3 BOREAS study for patients with post-essential thrombocythemia myelofibrosis (Post-ET-MF) who are relapsed or refractory to JAK inhibitor therapy. This novel oral MDM2 inhibitor restores p53 activity to induce apoptosis in TP53 wild-type cells. The study is determining the optimal dosing and comparing navtemadlin’s efficacy and safety to the best available therapy.
JNJ-88549968, sponsored by Janssen Research & Development, LLC, is a first-in-human T-cell redirecting bispecific antibody designed to bind CD3 on T cells and mutant calreticulin (CALR) on cancer cells in essential thrombocythemia. The drug aims to stimulate the immune system to eliminate CALR-mutated cells. This Phase 1 study is determining the recommended Phase 2 dose and dosing schedule while evaluating safety in CALR-mutated myeloproliferative neoplasms.
AJ1-11095 is being evaluated in a Phase 1 clinical trial sponsored by Ajax Therapeutics, Inc., targeting patients with post-essential thrombocythemia myelofibrosis (PET-MF) who have failed prior Type I JAK2 inhibitor therapy. This first-in-human study is examining the safety, tolerability, pharmacokinetics, and clinical activity of AJ1-11095, a novel, oral, type II JAK2 inhibitor designed to overcome resistance mechanisms seen with earlier-generation therapies.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Essential Thrombocythemia (ET) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for essential thrombocythemia (ET). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into essential thrombocythemia (ET) collaborations, regulatory environments, and potential growth opportunities.
Cancer Screening Market Report and Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share